Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy

Casale, Thomas B.; Bernstein, Jonathan A.; Maurer, Marcus; Saini, Sarbjit S.; Trzaskoma, Benjamin; Chen, Hubert; Grattan, Clive; Giménez‐Arnau, Ana; Kaplan, Allen P.; Rosén, Karin

doi:10.1016/j.jaip.2015.04.015

Cited by 72 publications

(58 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Real‐world experience also corroborates this: long‐term (>1‐year) use of omalizumab has been considered safe in two small retrospective studies and in individual case studies . Phase III data show a slight increase in sinusitis (4.9% vs. 2.1%), viral upper respiratory tract infection (0.5% vs. 0%), arthralgia (2.9% vs. 0.4%), headache (6.1% vs. 2.9%) and cough (2.2% vs. 1.2%) with omalizumab 300 mg compared to placebo . Anaphylaxis has been estimated to occur in 0.1–0.2% of patients with allergic asthma; however, no cases of anaphylaxis were reported in the phase III trials of omalizumab in CSU.…”

Section: Use Of Omalizumab For the Management Of Csu In The Real‐worlmentioning

confidence: 59%

“…Response to omalizumab in the real‐world clinical setting in patients with CSU has been shown to be similar to, and in some cases better than that seen in the pivotal randomized controlled trials (Table ) …”

Section: Practical Management Of Urticaria With Omalizumab In the Reamentioning

confidence: 78%

“…In the pivotal randomized clinical trials ASTERIA I, ASTERIA II and GLACIAL, omalizumab demonstrated excellent efficacy and safety for the treatment of CSU, with significant reductions in CSU signs and symptoms compared with placebo . Mean changes in weekly Itch Severity Score from baseline to week 12 were significantly greater with omalizumab 300 mg compared to placebo (‐67% in ASTERIA I, ‐71% in ASTERIA II and ‐62% in GLACIAL) . Significantly more patients had well controlled CSU (7‐day Urticaria Activity Score [UAS7]≤6) at week 12 following omalizumab 300 mg (52–66% of patients), compared with placebo (11–19% of patients) .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria

Giménez‐Arnau

Toubi

Marsland

et al. 2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Omalizumab is approved for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to/who remain symptomatic despite H 1 -antihistamine treatment, and has demonstrated good efficacy and safety in the clinical trial setting. Real-life clinical experience with omalizumab can be explored to address important practical questions relating to its use in CSU patients.Some experts have proposed that a consensus algorithm, covering various aspects to consider when using omalizumab in real-life clinical practice for the management of CSU, could answer many of these questions.

show abstract

Section: Use Of Omalizumab For the Management Of Csu In The Real‐worlmentioning

confidence: 59%

Section: Practical Management Of Urticaria With Omalizumab In the Reamentioning

confidence: 78%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria

Giménez‐Arnau

Toubi

Marsland

et al. 2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Dear Editor , Omalizumab has been shown to be a very effective drug in treating chronic spontaneous urticaria (CSU), improving patients’ quality of life . The phase III clinical trials ASTERIA I/II and GLACIAL showed, respectively, 58·8% and 52·4% of patients achieving a twice‐daily average Urticaria Activity Score 7 (UAS7td) ≤ 6 at week 12 . Outside of clinical trials, the response varies between 77% and 83% .…”

Section: Demographic and Clinical Variables Of The Study Population (mentioning

confidence: 99%

Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria

et al. 2018

View full text Add to dashboard Cite

“…Casale i wsp. [16] przeanalizowali dane z powyższych badań, porów-nując obie grupy pacjentów. Nie stwierdzono różnic w skuteczności omalizumabu w zależności od stosowanej terapii podstawowej PPS.…”

Section: Omalizumabunclassified

Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience

Dawicka¹,

Wilkowska²,

Grubska-Suchanek³

et al. 2016

View full text Add to dashboard Cite

StreSzczeniePokrzywka przewlekła charakteryzuje się występowaniem bąbli pokrzywkowych i/lub obrzęku naczynioruchowego w ciągu przynajmniej 6 tygodni. Według obecnych wytycznych, jeżeli terapia lekami przeciwhistaminowymi anty-H1 II generacji w czterokrotnych zalecanych dawkach jest nieskuteczna, zaleca się dołączenie do leków przeciwhistaminowych omalizumabu, cyklosporyny A lub montelukastu. Niniejsza praca przedstawia przegląd piśmiennictwa oraz doświad-czenia własne w zakresie możliwości zastosowania omalizumabu u dwóch pacjentek z rozpoznaniem pokrzywki przewlekłej spontanicznej. U obu chorych zastosowano rozmaite metody terapeutyczne, w tym leki przeciwhistaminowe anty-H1 w zalecanych przez europejskie wytyczne dużych dawkach (czterokrotnie większych od dawki podstawowej), glikokortykosteroidy doustne, montelukast oraz metotreksat, nie osiągnięto jednak zadowalającej kontroli objawów. Podczas leczenia omalizumabem u obu pacjentek udało się osiągnąć zdecydowaną poprawę stanu klinicznego, a mianowicie redukcję w Skali średniego nasilenia objawów pokrzywki w ciągu 7 dni (UAS7) -u pierwszej chorej z 34 do 11,8 pkt, a u drugiej z 41 do 5,76 pkt. AbStrActChronic urticaria is a condition characterized by the appearance of wheals and/or angioedema that last for at least 6 weeks. According to the recent recommendations, if H1-antihistamines used in four times licensed doses remain ineffective, add-on treatment with omalizumab, cyclosporine A or montelukast should be applied. This paper offers a literature review of the studies on using omalizumab in chronic spontaneous urticaria (CSU) treatment. Moreover, it presents our own experience with the use of omalizumab in the treatment of two patients with CSU. Both patients were treated with H1-antihistamines in four times licensed doses recommended by European guidelines, oral corticosteroids, montelukast, and methotrexate -all without satisfactory results. During the time of the omalizumab therapy both patients achieved a significant improvement measured by the decrease in the Average Urticaria Activity Score for 7 days (UAS7) -the first patient from 34 to 11.8 points, the second one from 41 to 5.76.

show abstract

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy

Abstract: Omalizumab 300 mg was safe and effective in reducing CIU/CSU symptoms regardless of background therapy.

Cited by 72 publications

References 19 publications

Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria

Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria

Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria

Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience

Contact Info

Product

Resources

About